Marksans Pharma Ltd - Pharmaceutical Company India
Follow Us On :
  • About Us
    • Company Profile
    • From the Chairman's Desk
    • Vision, Core Values
    • Milestones
    • Board of Directors
    • Management Profile
    • Mergers & Acquisitions
    • International Operations
    • Strategy
    • Subsidiaries
      •  
      • Bell, Sons & Co. (Druggists) Ltd.
      • Nova Pharmaceuticals Australasia Pty Ltd.
      • Relonchem Limited
      • Time Cap Labs, Inc.
      •  
    • R & D Capabilities
    • Quality Policy
    • World Wide Operations
  • Formulation Business
    • Overview
    • Markets
      •  
      • USA
      • Europe
      • South East Asia
      • Africa
      • Russia & CIS
      • Latin America
      • Australasia
      •  
    • Manufacturing Facilities
      •  
      • Locations (Goa/ Southport - UK)
      •  
  • R & D
    • CRAMS
    • Out Licensing
    • Business Development
  • Investor Relations
    • General Information & Investor Contact
      •  
      • General Information
      • Investor Contact
      •  
    • Corporate Announcements
    • Financial Results
      •  
      • Quarterly Results
      • Annual Reports
      • Subsidiary Accounts
      • Investors Presentation
      •  
    • Compliances
      •  
      • Shareholding Pattern
      • Corporate Governance
      • Codes & Policies
      • Independent Directors
      • Investors Grievance Report
      • Shareholders Meeting
      • Unclaimed Dividend
      • Shares Liable for Transfer to IEPF
      • CSR Activities
      • Others Disclosures
      • Forms
    • Press Release
    • PD
  • Industry Overview
  • Health and Illness
    • Oncology And Critical Care
    • The Disorders Of The Mind And Nerves
      •  
      • Neurological Disorder
      • Mental Disorders
      •  
    • Skin Infections And Ulcers
    • Gastro - Intestinal Disorders (GI)
    • Cough Remedies
    • Women's Health
    • Bacterial Infections And Its Treatment
  • Blog
  • Careers
    • Overview
    • Values
    • Life at Marksans
  • Contact Us
  • Home
  • About Us
    • Company Profile
    • From the Chairman's Desk
    • Vision, Core Values
    • Milestones
    • Board of Directors
    • Management Profile
    • Mergers & Acquisitions
    • International Operations
    • Strategy
    • Subsidiaries
      • Bell, Sons & Co. (Druggists) Ltd.
      • Nova Pharmaceuticals Australasia Pty Ltd.
      • Relonchem Limited
      • Time Cap Labs, Inc.
    • R & D Capabilities
    • Quality Policy
    • World Wide Operations
  • Formulation Business
    • Overview
    • Markets
      • USA
      • Europe
      • South East Asia
      • Africa
      • Russia & CIS
      • Latin America
    • Manufacturing Facilities
      • Locations (Goa/ Southport - UK)
  • R & D
    • CRAMS
    • Out Licensing
    • Business Development
  • Investor Relations
    • General Information & Investor Contact
      • General Information
      • Investor Contact
    • Corporate Announcements
    • Financial Results
      • Quarterly Results
      • Annual Reports
      • Subsidiary Accounts
      • Investors Presentation
    • Compliances
      • Shareholding Pattern
      • Corporate Governance
      • Codes & Policies
      • Independent Directors
      • Investors Grievance Report
      • Shareholders Meeting
      • Unclaimed Dividend
      • Shares Liable for Transfer to IEPF
      • CSR Activities
      • Others Disclosures
      • Forms
    • Press Release
    • PD
  • Industry Overview
  • Health and Illness
    • Oncology And Critical Care
    • The Disorders Of The Mind And Nerves
      • Neurological Disorder
      • Mental Disorders
    • Skin Infections And Ulcers
    • Gastro - Intestinal Disorders (GI)
    • Cough Remedies
    • Women's Health
    • Bacterial Infections And Its Treatment
  • Blog
  • Careers
    • Overview
    • Values
    • Life at Marksans
  • Contact Us
  • Site Map

Investor Relations

  • General Information & Investor Contact
  • Corporate Announcements
  • Financial Results
  • Compliances
    • Shareholding Pattern
    • Corporate Governance
    • Codes & Policies
    • Independent Directors
    • Investors Grievance Report
    • Shareholders Meeting
    • Unclaimed Dividend
    • Shares Liable for Transfer to IEPF
    • CSR Activities
    • Others Disclosures
    • Forms
  • Press Release
  • PD
Corporate Social Responsibility by Marksans Pharma Ltd

Home Investor Relations Compliances

Codes & Policies

  • Nomination and Remuneration Policy
  • Policy on material subsidiary
  • Policy on materiality of related party transactions
    and on dealing with related party transactions
  • Code of Conduct to regulate, monitor and report
    trading in the securities of Marksans Pharma Limited
  • Archival Policy
  • Code of Conduct for Directors and Employees
  • Code of Practice nd procedure for Fair Disclosure of Unpublished Price Sensitive Information
  • Corporate Social Responsibility Policy
  • Whistle Blower Policy
  • Dividend Distribution Policy
  • Policy for determination of materiality of events or information and disclosures
  • Home
  • About Us
    • Company Profile
    • From the Chairman's Desk
    • Vision, Core Values
    • Milestones
    • Board of Directors
    • Management Profile
    • Mergers & Acquisitions
  • Careers
    • Overview
    • Values
    • Life at Marksans
  • Contact Us
  •  
  •  
    • International Operations
    • Strategy
    • Subsidiaries
    • R & D Capabilities
    • Quality Policy
    • World Wide Operations
  • Industry Overview
  • Blog
  • Site Map
  • Formulation Business
    • Overview
    • Markets
    • Manufacturing Facilities
  • Health and Illness
    • Oncology And Critical Care
    • The Disorders Of The Mind And Nerves
    • Skin Infections And Ulcers
    • Gastro - Intestinal Disorders (GI)
    • Cough Remedies
    • Women's Health
    • Bacterial Infections And Its Treatment
  • R & D
    • CRAMS
    • Out Licensing
    • Business Development
  • Investor Relations
    • General Information & Investor Contact
    • Corporate Announcements
    • Financial Results
    • Compliances
    • Press Release
    • PD
© Copyright 2013 Marksans Pharma.